

I BEST OF THE WEEK (19 dic – 25 dic 2022)

Jun Yasuhara et al.

Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults A Systematic Review and Meta-analysis

JAMA, December 2022; doi:10.1001/jamapediatrics.2022.4768

Abstract

Importance Published data on COVID-19 mRNA vaccine–associated myopericarditis in adolescents and young adults have been derived from small case series, national populationbased studies, or passive reporting systems. Pooled evidence from a larger, international cohort is scarce.

Objective

To investigate the clinical features and early outcomes associated with myopericarditis after COVID-19 mRNA vaccination in a heterogeneous population of adolescents and young adults. **Data Sources** PubMed and EMBASE were searched through August 2022. **Language restrictions** were not applied. **Study Selection** Observational studies and case series describing COVID-19 vaccine– associated myopericarditis in adolescents and young adults aged 12 to 20 years and reporting clinical characteristics and early outcomes were included.

Conclusions and Relevance

This systematic review and meta-analysis found low incidence rate and largely favorable early outcomes of COVID-19 mRNA vaccine–associated myopericarditis in adolescents and young adults from a wide range of populations. These findings are reassuring but continued follow-up is warranted